Cystatin C and cognitive impairment 10 years later in older women.
Yelena Slinin, Katherine W Peters, Areef Ishani, Kristine Yaffe, Howard A Fink, Katie L Stone, Michael Steffes, Kristine E Ensrud, Study of Osteoporotic Fractures
Author Information
Yelena Slinin: Department of Medicine, University of Minnesota, Minneapolis. Department of Medicine, Minneapolis VA Health Care System, Minnesota. slini001@umn.edu.
Katherine W Peters: California Pacific Medical Center Research Institute, San Francisco.
Areef Ishani: Department of Medicine, University of Minnesota, Minneapolis. Department of Medicine, Minneapolis VA Health Care System, Minnesota.
Kristine Yaffe: Department of Psychiatry, Neurology, and Epidemiology & Biostatistics, University of California, San Francisco.
Howard A Fink: Department of Medicine, University of Minnesota, Minneapolis. Department of Medicine, Minneapolis VA Health Care System, Minnesota. Division of Epidemiology & Community Health and.
Katie L Stone: California Pacific Medical Center Research Institute, San Francisco.
Michael Steffes: Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.
Kristine E Ensrud: Department of Medicine, University of Minnesota, Minneapolis. Department of Medicine, Minneapolis VA Health Care System, Minnesota. Division of Epidemiology & Community Health and.
BACKGROUND: Results of prospective studies examining the association between cystatin C and incident cognitive impairment have been inconsistent. We tested the hypothesis that there is a U-shaped association in older women between cystatin C and risk of incident cognitive impairment 10 years later. METHODS: We conducted a longitudinal analysis of a prospective cohort of 1,332 community-dwelling elderly women without dementia at baseline who had baseline cystatin C and serum creatinine measurements and completed an extended cognitive battery of neuropsychological tests with determination of cognitive status 10 years later. Incident cognitive impairment was defined as either new onset of adjudicated diagnosis of mild cognitive impairment or dementia. RESULTS: Incident mild cognitive impairment or dementia was identified among 140 (26.0%) women in quartile 1 (Q1), 122 (22.6%) in Q2, 121 (22.5%) in Q3, and 156 (28.9%) in Q4 of cystatin C. In the fully adjusted model, compared to women in Q2-Q3 of cystatin C, adjusted odds ratios (95% CI) for incident cognitive impairment were 1.31 (0.98-1.75) for Q1, and 1.25 (0.94-1.66) for Q4 Compared to women in Q2-Q3 of estimated glomerular filtration rate (eGFRCysC), adjusted odds ratios (95% CI) for incident cognitive impairment after 10 years of follow-up were 1.18 (0.88-1.58) for Q4 (eGFRCysC 76.1-109.4mL/min/1.73 m(2)) and 1.26 (0.94-1.67) for Q1 (eGFRCysC 21.8-55.5mL/min/1.73 m(2)). CONCLUSIONS: These results support a U-shaped association between cystatin C concentration and risk of cognitive impairment or dementia 10 years later, but the association is not independent of potential confounding factors.
